Your browser doesn't support javascript.
loading
Outcome-based reimbursement in Central-Eastern Europe and Middle-East.
Ádám, Ildikó; Callenbach, Marcelien; Németh, Bertalan; Vreman, Rick A; Tollin, Cecilia; Pontén, Johan; Dawoud, Dalia; Elvidge, Jamie; Crabb, Nick; van Waalwijk van Doorn-Khosrovani, Sahar Barjesteh; Pisters-van Roy, Anke; Vincziczki, Áron; Almomani, Emad; Vajagic, Maja; Oner, Z Gulsen; Matni, Mirna; Fürst, Jurij; Kahveci, Rabia; Goettsch, Wim G; Kaló, Zoltán.
Afiliação
  • Ádám I; Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
  • Callenbach M; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.
  • Németh B; Syreon Research Institute, Budapest, Hungary.
  • Vreman RA; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.
  • Tollin C; National Health Care Institute, Zorginstituut Nederland, Diemen, Netherlands.
  • Pontén J; The Dental and Pharmaceutical Benefits Agency, Tandvårds- och Låkemedelsförmånsverket, Stockholm, Sweden.
  • Dawoud D; The Dental and Pharmaceutical Benefits Agency, Tandvårds- och Låkemedelsförmånsverket, Stockholm, Sweden.
  • Elvidge J; National Institute for Health and Care Excellence, London, United Kingdom.
  • Crabb N; Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • van Waalwijk van Doorn-Khosrovani SB; National Institute for Health and Care Excellence, London, United Kingdom.
  • Pisters-van Roy A; National Institute for Health and Care Excellence, London, United Kingdom.
  • Vincziczki Á; Department of Medical Advisory and Innovation, Centraal Ziekenfonds (CZ) Health Insurance, Tilburg, Netherlands.
  • Almomani E; Department of Medical Advisory and Innovation, Centraal Ziekenfonds (CZ) Health Insurance, Tilburg, Netherlands.
  • Vajagic M; National Health Insurance Fund of Hungary, Nemzeti Egészségbiztosítási Alapkezelõ, Budapest, Hungary.
  • Oner ZG; Department for Health Technology Assessment, Jordanian Royal Medical Services, Amman, Jordan.
  • Matni M; Croatian Health Insurance Fund, Zagreb, Croatia.
  • Fürst J; Social Security Institution of Turkey, Ankara, Turkey.
  • Kahveci R; Social Security Main Office, Caisse Nationale de la Sécurité Sociale, Beirut, Lebanon.
  • Goettsch WG; Department of Drugs, Health Insurance Institute of Slovenia, Ljubljana, Slovenia.
  • Kaló Z; Pharmaceutical Policies and Governance, Management Sciences for Health, Kyiv, Ukraine.
Front Med (Lausanne) ; 9: 940886, 2022.
Article em En | MEDLINE | ID: mdl-36213666
Outcome-based reimbursement models can effectively reduce the financial risk to health care payers in cases when there is important uncertainty or heterogeneity regarding the clinical value of health technologies. Still, health care payers in lower income countries rely mainly on financial based agreements to manage uncertainties associated with new therapies. We performed a survey, an exploratory literature review and an iterative brainstorming in parallel about potential barriers and solutions to outcome-based agreements in Central and Eastern Europe (CEE) and in the Middle East (ME). A draft list of recommendations deriving from these steps was validated in a follow-up workshop with payer experts from these regions. 20 different barriers were identified in five groups, including transaction costs and administrative burden, measurement issues, information technology and data infrastructure, governance, and perverse policy outcomes. Though implementing outcome-based reimbursement models is challenging, especially in lower income countries, those challenges can be mitigated by conducting pilot agreements and preparing for predictable barriers. Our guidance paper provides an initial step in this process. The generalizability of our recommendations can be improved by monitoring experiences from pilot reimbursement models in CEE and ME countries and continuing the multistakeholder dialogue at national levels.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Guideline / Health_technology_assessment / Prognostic_studies Idioma: En Revista: Front Med (Lausanne) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Hungria

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Guideline / Health_technology_assessment / Prognostic_studies Idioma: En Revista: Front Med (Lausanne) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Hungria